You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SB 277011A dihydrochloride
Biological Activity for SB 277011A dihydrochloride
SB 277011A dihydrochloride is a selective dopamine D3 receptor antagonist (pKi values are 8.0, 6.0, 5.0 and <5.2 for D3, D2, 5-HT1D and 5-HT1B respectively). Brain penetrant.
Sold for research purposes under agreement from GlaxoSmithKline.
Technical Data for SB 277011A dihydrochloride
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SB 277011A dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SB 277011A dihydrochloride
The following data is based on the product molecular weight 511.49. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||3.91 mL||19.55 mL||39.1 mL|
|2.5 mM||0.78 mL||3.91 mL||7.82 mL|
|5 mM||0.39 mL||1.96 mL||3.91 mL|
|25 mM||0.08 mL||0.39 mL||0.78 mL|
Product Datasheets for SB 277011A dihydrochloride
References for SB 277011A dihydrochloride
References are publications that support the biological activity of the product.
Reavill et al (2000) Pharmacological actions of a novel, high-affinity, and selective human DA D3 receptor antagonist, SB-277011-A. J.Pharmacol.Exp.Ther. 294 1154 PMID: 10945872
Stemp et al (2000) Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective DA D3 receptor antagonist with high oral bioavailability and CNS pe J.Med.Chem. 43 1878 PMID: 10794704
If you know of a relevant reference for SB 277011A dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: SB 277011A dihydrochloride, SB 277011A dihydrochloride supplier, SB277011A, dihydrochloride, dopamine, dopaminergic, receptors, antagonists, selective, d3, D3, Receptors, 4207, Tocris Bioscience
1 Citation for SB 277011A dihydrochloride
Citations are publications that use Tocris products. Selected citations for SB 277011A dihydrochloride include:
Chen et al (2013) Electroacupuncture reduces cocaine-induced seizures and mortality in mice. Nat Neurosci 2013 134610 PMID: 23690833
Do you know of a great paper that uses SB 277011A dihydrochloride from Tocris? Please let us know.
Reviews for SB 277011A dihydrochloride
There are currently no reviews for this product. Be the first to review SB 277011A dihydrochloride and earn rewards!
Have you used SB 277011A dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.